S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023

Best Stocks Under $10.00 Right Now

Best Stocks Under $10.00

A common mistake among novice investors is confusing an undervalued stock with a cheap stock. When a stock trades under $5 (often called penny stocks), it can be easy for an investor to understand why the stock carries such a low price. But when a stock trades below $10, a little more research is required. This is particularly true when the broader market is in a sell-off. Before attempting to buy stocks that are trading for less than 10 dollars, there are some important things to know.

If you’re an experienced investor this is just a basic review. But if you’re a relatively new investor this may help answer a lot of questions.

To understand why buying stocks under $10 can come with an elevated risk you need to understand how a company’s stock price is calculated. There are two data points to look for.

The first is a company’s market capitalization (or market cap). That is a rough estimation of how much a company is worth. The second number is the number of outstanding shares (also called shares outstanding – the meaning is the same). This is, as the name suggests, the number of common shares available to be bought.

To calculate a company’s stock price, you divide the company’s current market capitalization by its number of outstanding shares.

Here’s an example that keeps the math easy. A stock that is valued at $100 million and has 1 million outstanding shares has a share price of $100. But a stock that is valued at $100 million and has 100 million outstanding shares has a share price of $10.

The important thing to take away from that example is a stock’s price does not necessarily reflect the market value of the company.

Now here’s a real world example. On March 27, General Electric (NYSE:GE) had a market cap of $66.37 billion. The company had 8.74 billion outstanding shares. When you divide the market cap by the outstanding shares you get 7.59.

66.37/8.74 = 7.59

This means at that moment, one share of GE stock was valued at $7.59.

The simple answer is “Of course you should.” A common fallacy among even the most experienced investors is failing to understand the difference between a stock that is cheap and one that is undervalued. It’s an interesting aspect of human psychology. A stock that is trading at $200 could decline by 25% and investors will swoop in to buy it “on sale”. But if a $12 stock drops 20% it becomes untouchable.

The problem with this approach is it assumes that a high price is good and a low price is bad. And in fairness, that can be true. Many stocks that trade under $10 do so because they present obvious and fundamentally problematic issues that are suppressing their growth.

So if you’re an investor who is looking to buy stocks under $10 is be sure you’re ready, and able, to do some research. Simply throwing your hard-earned money at a stock because you’ve heard the mantra “buy low, sell high” is foolish.

But the same can be said of investing in any stock. And if you’re reading this article, I hope you already understand that stocks over time can be an excellent and sound investment. Stock prices, no matter the price, can fluctuate wildly. But over time, investing in stocks has proven to be the most reliable path to reaching your financial goals.

And the simple truth is that a stock that is trading under $10 can offer you the ability to make huge gains. But that is, if you know what to look for. Fortunately, in this article, we’ve done a lot of that research for you.

But there is one caveat about investing in stocks under $10. This should only make up a small portion of the stock portion of your portfolio. The majority of your investment in equities (another name for stocks) should focus on solid, stable companies. And depending on your investment style, you should look for companies that pay a dividend.

You should also not invest in stocks under $10 to replace money you have set aside in bonds or cash. This should be money that you are already investing in the market.

The reward of buying stocks under $10 is the opportunity for growth. If you can buy 1000 shares of a stock that is trading at $8, you would only need the stock to increase in value by $8 to double your investment. If you were

That, however, is easier said than done. And many investors have seen that $8,000 investment evaporate as they bought shares of a falling knife. Still, if investors can find the right stock, stocks under $10 are one of the best ways to capture a significant gain without a large investment.

That brings up a second point. Stocks under $10 are more accessible for investors without a lot of money to put into the market. Robinhood and other trading apps are designed on this principle. If you only have a small amount of money to invest, you don’t have to put all your eggs in one basket. In practical terms, and investor with $10,000 to invest could buy over 150 shares a stock that is currently trading below $7 a share.

This also makes stocks under $10 a great option for diversification. Not only can you look at different sectors, but you can also dabble in international stocks.

Here are some of the most common risks of buying stocks under $10:

  • Share dilution - Generally, the number of outstanding shares is driven by simple supply and demand. A company that issues a solid earnings report, or comes out with a new product, etc. will see their outstanding shares decline because there will be more buyers than sellers.

    In other words, the stock is harder to buy. If an investor wants to buy it, a seller will demand a higher price to let their shares go. And when there are more sellers than buyers, there will be a higher number of outstanding shares. In other words, sellers have to accept a lower price for the shares they purchased to entice a buyer to buy.

    However, when a company gets into financial trouble, it becomes difficult for them to get loans. When a company has limited free cash flow (FCF), they are seen as a credit risk. This simply means lenders believe there is a high probability that the company will default on the loan.

    When this happens, one strategy they may execute is to issue more shares. This almost always dilutes the value of the existing shares, which in turn drives the price down further.

  • Increased competition - Young startup companies often have a first mover advantage. Because they are creating a new market, they have no competition and have no price pressure. However, as more competitors enter the market, a company may face pressure both on the price they charge and their profit margin. If the company is slow to adapt to the competition, their stock price may sink to extremely low levels.

  • The company operates in a cyclical industry - A retailer may see their stock spike during the holiday season as investors anticipate greater revenue and profit. However, for the remainder of the year, the company may not be able to sustain that revenue. That’s another reason the stock may sink.

  • The stock is low- to no-growth stock - If you look at the price history of a stock, it may just trade in a specific range. In that case, a stock under $10 may still be a worthwhile investment if it pays a nice dividend.

If you’ve followed this article and understand both the pros and cons of stocks under $10, let’s take a look at how you can put that information to work in the middle of one of the greatest stock sell-offs in history.

On the one hand, there are a number of quality companies that have seen their share price reach uncomfortably low levels. But some of these stocks are in industries like hospitality that have been particularly affected by the coronavirus. And while these stocks are generally perceived to see increased, pent-up demand once the coronavirus threat recedes, it may be some time before this increased demand shows up in the stock price.

Value investing opportunities do exist—if you're looking in the right places. Putting together a list of the best stocks under $10.00 requires investors to do their homework. At a price of under $10, these companies are not penny stocks. In fact many companies have a large market cap. But just because a stock is trading for a low price doesn’t make it a great value.

One of the biggest assets an investor can have is time. If you’ve done your due diligence and believe in the overall financial health and direction of the company, buying stocks under $10 can be very profitable. If you have the time and patience to hold the stock through many economic cycles, here are some stocks to consider.

 


JD Sports Fashion stock logo

#1 - JD Sports Fashion

OTCMKTS:JDSPY
Stock Price: $1.95
Average Trading Volume: 3,229 shares
Consensus Rating: Strong Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $205.83 (10,455.6% Upside)
JD Sports Fashion plc engages in the retail of branded sports fashion and outdoor clothing, footwear, accessories, and equipment for kids, women, and men. It operates through Sports Fashion and Outdoor segments. The company also retails leisure goods, sports goods, fishing gear, camping goods, boats, and bicycles, as well as distributes sports apparel and accessories, footwear, and apparel. It offers its products under the JD, Size?, Footpatrol, Finish Line, Shoe Palace, DTLR, Livestock, Sprinter, Sport Zone, Sizeer, JD Gyms, Tessuti, Scotts, Go Outdoors, Blacks, Millets, Tiso, Ultimate Outdoors, Fishing Republic, and Naylors brands. The company also operates online business. In addition, it licenses fashion brands and operates fitness centers; operates as online own label women's fashion retailer; and manufactures and distributes professional fitness equipment. The company has operations in the United Kingdom, Andorra, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Latvia, Lithuania, Malaysia, the Netherlands, New Zealand, Poland, Portugal, Republic of Ireland, Romania, Serbia, Singapore, Slovakia, South Korea, Spain and the Canary Islands, Sweden, Thailand, and the United Arab Emirates. The company was founded in 1981 and is headquartered in Bury, the United Kingdom. JD Sports Fashion plc is a subsidiary of Pentland Group Limited.
Bird Construction stock logo

#2 - Bird Construction

OTCMKTS:BIRDF
Stock Price: $6.55
PE Ratio: 9.58
Average Trading Volume: 1,746 shares
P/E Ratio: 9.6
Dividend Yield: 6.68%
Consensus Rating: Strong Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.80 (64.9% Upside)
Bird Construction Inc. provides construction services in Canada. The company primarily focuses on projects in the industrial, commercial, and institutional, and civil infrastructure markets. It constructs large, complex industrial buildings, including manufacturing, processing, distribution, and warehouse facilities; and provides electrical and instrumentation, high voltage testing and commissioning services, as well as power line construction, structural, mechanical, and piping, including off-site metal and modular fabrication. The company also engages in the civil construction operations, such as site preparation and earthworks, underground piping, utilities and foundation, and other concrete services, as well as mine support and greenfield and brownfield hydroelectric construction service; and civil infrastructure operations comprising road, bridge, rail, and underground utilities installation. In addition, it constructs and retrofits institutional facilities, include healthcare facilities, post-secondary education facilities, K-12 schools, recreation facilities, public transportation facilities, prisons, courthouses, government buildings, and long term care and senior housing facilities; and constructs and residential sector, include new construction and retrofit of data centers, office buildings, retail facilities, film studio infrastructure, hotels, and mixed-use mid- to high-rise residential buildings. Further, it offers electrical and related system services, which include electrical and mechanical infrastructure design and installation, data communications, security, and lifecycle services. It serves clients in the oil and gas, liquefied natural gas, mining, renewables, water and wastewater, nuclear, infrastructure, and residential sectors. Bird Construction Inc. was founded in 1920 and is based in Mississauga, Canada.
InflaRx stock logo

#3 - InflaRx

NASDAQ:IFRX
Stock Price: $3.65 (+$0.08)
PE Ratio: -5.89
Market Cap: $163.16 million
Average Trading Volume: 1.13 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $14.00 (283.6% Upside)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Avidity Biosciences stock logo

#4 - Avidity Biosciences

NASDAQ:RNA
Stock Price: $9.35 (+$0.42)
PE Ratio: -2.78
Market Cap: $662.17 million
Average Trading Volume: 1.09 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $38.17 (308.2% Upside)
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Passage Bio stock logo

#5 - Passage Bio

NASDAQ:PASG
Stock Price: $0.81 (-$0.04)
PE Ratio: -0.39
Market Cap: $44.31 million
Average Trading Volume: 202,524 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.40 (935.8% Upside)
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Endeavour Silver stock logo

#6 - Endeavour Silver

NYSE:EXK
Stock Price: $3.02
PE Ratio: -301.50
Market Cap: $577.40 million
Average Trading Volume: 2.38 million shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.04 (100.2% Upside)
Endeavour Silver Corp., a silver mining company, engages in the acquisition, exploration, development, extraction, processing, refining, and reclamation of mineral properties in Mexico and Chile. The company explores for gold and silver deposits, and precious metals. The company was formerly known as Endeavour Gold Corp. and changed its name to Endeavour Silver Corp. in September 2004. Endeavour Silver Corp. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Beazley stock logo

#7 - Beazley

OTCMKTS:BZLYF
Stock Price: $7.00 (-$0.03)
Average Trading Volume: 3,892 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $815.40 (11,548.6% Upside)
Beazley plc provides risk insurance and reinsurance solutions in the United States, Europe, and internationally. It operates through Cyber Risks, Digital, MAP Risks, Property Risks, and Specialty Risks segments. The Cyber Risk segment underwrites cyber and technology risks. The Digital segment underwrites various marine, contingency, and SME liability risks through digital channels, such as e-trading platforms and broker portals. The MAP Risks segment underwrites marine, portfolio underwriting and political, and contingency business. The Property Risks segment underwrites first party property risks and reinsurance business. The Specialty Risks segment underwrites liability classes, including employment practices risks and directors and officers, as well as healthcare, lawyers, and international financial institutions. It also underwrites life, health, and personal accident; and jewelry, fine art, and specie products risk insurance. The company was founded in 1986 and is based in London, the United Kingdom.
Crew Energy stock logo

#8 - Crew Energy

OTCMKTS:CWEGF
Stock Price: $4.67 (+$0.15)
PE Ratio: -1.50
Average Trading Volume: 30,047 shares
Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.00 (71.3% Upside)
Crew Energy Inc. engages in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGL) in Canada. Its principal properties include Montney oil and liquids-rich natural gas assets comprising Septimus, West Septimus, Groundbirch, and Tower in northeast British Columbia. The company was incorporated in 2003 and is headquartered in Calgary, Canada.
23andMe stock logo

#9 - 23andMe

NASDAQ:ME
Stock Price: $1.52 (-$0.23)
PE Ratio: -2.20
Market Cap: $698.81 million
Average Trading Volume: 2.18 million shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.50 (263.0% Upside)
23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications; and Lemonaid telehealth platform, patients can access affiliated licensed healthcare professionals for medical consultation and treatment for several common conditions, as well as research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline plc to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Longboard Pharmaceuticals stock logo

#10 - Longboard Pharmaceuticals

NASDAQ:LBPH
Stock Price: $6.49 (-$0.32)
PE Ratio: -2.55
Market Cap: $156.42 million
Average Trading Volume: 85,122 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $17.40 (168.1% Upside)
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Cipher Mining stock logo

#11 - Cipher Mining

NASDAQ:CIFR
Stock Price: $3.68 (-$0.05)
PE Ratio: -30.67
Market Cap: $916.10 million
Average Trading Volume: 1.45 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.10 (11.4% Upside)
Cipher Mining Inc., a technology company, develops and operates industrial scale bitcoin mining data centers in the United States. The company was incorporated in 2020 and is based in New York, New York. Cipher Mining Inc. is a subsidiary of Bitfury Holding B.V.
Lucero Energy stock logo

#12 - Lucero Energy

OTCMKTS:PSHIF
Stock Price: $0.45 (+C$0.01)
PE Ratio: -0.63
Average Trading Volume: 23,106 shares
Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: C$0.90 (100.0% Upside)
Lucero Energy Corp., an independent energy company, engages in the acquisition, development, and production of oil and natural gas assets primarily in the Bakken and Three Forks formations in the Williston Basin area of North Dakota. The company was formerly known as PetroShale Inc. and changed its name to Lucero Energy Corp. in May 2022. Lucero Energy Corp. is headquartered in Calgary, Canada.
Atreca stock logo

#13 - Atreca

NASDAQ:BCEL
Stock Price: $0.90 (+$0.01)
PE Ratio: -0.37
Market Cap: $35.24 million
Average Trading Volume: 141,302 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.75 (1,094.4% Upside)
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.
Allego stock logo

#14 - Allego

NYSE:ALLG
Stock Price: $2.35 (-$0.05)
Average Trading Volume: 90,598 shares
Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.70 (185.1% Upside)
Allego N.V. operates as an electric vehicle (EV) charging company. The company offers charging solutions for electric cars, motors, buses, and trucks. It has a charging network with renewable energy and charging solutions for business-to-business customers, including leading retail and auto brands. The company has approximately 28,000 charging ports in Europe. It also provides Allego EV Cloud, a customer payment tool that offers essential services to owned and third-party customers comprising authorization and billing, smart charging and load balancing, analysis, and customer support. The company was founded in 2013 and is based in Arnhem, the Netherlands.
Centrica stock logo

#15 - Centrica

OTCMKTS:CPYYY
Stock Price: $7.10 (-$0.08)
Market Cap: $9.85 billion
Average Trading Volume: 10,211 shares
Dividend Yield: 2.52%
Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $142.14 (1,903.4% Upside)
Centrica plc operates as an integrated energy company in the United Kingdom, Ireland, Scandinavia, North America, and internationally. The company operates through British Gas Services & Solutions, British Gas Energy, Centrica Business Solutions, Bord Gáis Energy, Energy Marketing & Trading, and Upstream segments. It supplies gas and electricity to residential, commercial, industrial customers, and small businesses, as well as offers energy-related services; and generates power from nuclear assets. The company also provides installation, repair, and maintenance services for domestic central heating, plumbing and drains, electrical appliances; and heating, ventilation, and air conditioning systems, as well as offers breakdown services. In addition, it is involved in the procurement, trading, and optimization of energy; procurement and sale of LNG; and supply of energy efficiency solutions and technologies. Further, the company produces and processes gas and oil; develops new fields to maintain reserves; constructs, owns, and exploits infrastructure; and engages in the social enterprise investment fund activities. Additionally, it provides vehicle leasing, commercial, and insurance services, as well as energy management products and services; constructs battery storage; builds solar farm and connects to grid; and operates a gas storage and franchise network. The company was formerly known as Yieldtop plc and changed its name to Centrica plc in December 1996. Centrica plc was founded in 1812 and is based in Windsor, the United Kingdom.
Capstone Copper stock logo

#16 - Capstone Copper

OTCMKTS:CSCCF
Stock Price: $4.78 (+C$0.03)
Average Trading Volume: 69,073 shares
Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: C$5.19 (8.5% Upside)
Capstone Copper Corp. operates as a copper mining company in the United States, Chile, and Mexico. The company explores for copper, silver, zinc, and other metals. It owns interests in the Pinto Valley copper mine located in Arizona, the United States; Mantos Blancos copper-silver mine located in the Antofagasta region, Chile; Mantoverde coppergold mine located in the Atacama region, Chile; and Cozamin copper-silver mine located in Zacatecas, Mexico. In addition, the company owns interest in the Santo Domingo copper-iron-gold-cobalt project located northeast of Mantoverde in the Atacama region, Chile; and a portfolio of exploration properties in the Americas. Capstone Copper Corp. is headquartered in Vancouver, Canada.
Outlook Therapeutics stock logo

#17 - Outlook Therapeutics

NASDAQ:OTLK
Stock Price: $1.64 (-$0.03)
Market Cap: $420.94 million
Average Trading Volume: 876,701 shares
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.50 (235.4% Upside)
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Blade Air Mobility stock logo

#18 - Blade Air Mobility

NASDAQ:BLDE
Stock Price: $3.82 (-$0.18)
PE Ratio: -10.05
Market Cap: $292.67 million
Average Trading Volume: 501,841 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.20 (114.7% Upside)
Blade Air Mobility, Inc. provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.
DarioHealth stock logo

#19 - DarioHealth

NASDAQ:DRIO
Stock Price: $3.44 (-$0.02)
PE Ratio: -2.39
Market Cap: $92.16 million
Average Trading Volume: 135,981 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.50 (205.2% Upside)
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Move, which helps to prevent and treat the most common MSK conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; Dario One, a full suite of chronic condition management solutions; DarioEngage platform; and Dario blood glucose monitoring system. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and Dario smart diabetes management solutions, including live clinical coaching, content, automated journeys, hardware, and lifestyle coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Arcutis Biotherapeutics stock logo

#20 - Arcutis Biotherapeutics

NASDAQ:ARQT
Stock Price: $9.39 (-$0.44)
PE Ratio: -1.65
Market Cap: $576.75 million
Average Trading Volume: 1.08 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $43.33 (361.5% Upside)
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Mondee stock logo

#21 - Mondee

NASDAQ:MOND
Stock Price: $7.36 (+$0.12)
PE Ratio: -5.71
Market Cap: $605.51 million
Average Trading Volume: 155,956 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $13.40 (82.1% Upside)
Mondee Holdings, Inc. operates as a travel technology company in the leisure and corporate travel markets in the United States and internationally. The company operates through two segments, Travel Marketplace and SaaS Platform. The Travel Marketplace segment primarily engages in sale of airline tickets through its platform. The SAAS Platform segment offers corporate travel cost savings solutions through its technology platform. The company connects a network of leisure travel and gig economy workers, vacation homes, hotels, packaged solutions, and ancillary offerings. The company was founded in 2011 and is headquartered in Austin, Texas.
Vor Biopharma stock logo

#22 - Vor Biopharma

NYSE:VOR
Stock Price: $2.62 (-$0.01)
PE Ratio: -1.21
Market Cap: $176.10 million
Average Trading Volume: 159,152 shares
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $15.93 (508.0% Upside)
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
D2L stock logo

#23 - D2L

OTCMKTS:DTLIF
Stock Price: $7.29
Average Trading Volume: 3,450 shares
Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: C$10.80 (48.1% Upside)
D2L Inc. cloud-based learning software for higher education institutions, kindergarten to grade 12 schools and districts, and private sector enterprises in Canada, the United States, and rest of world. The company offers Brightspace, a cloud-based learning platform that designs as the doorway to an all-in-one learning ecosystem; Performance+, an advanced predictive analytics package that comprising advanced analytics dashboards, insights report builder, the student success system, and D2L Brightspace LeaP; Creator+, an authoring system helping educators with authoring tools, game-based learning, awards leaderboard, Brightspace capture, and course catalogue; and D2L Wave, a free-to-use workforce education marketplace that simplifies the search for skill-aligned courses and programs for employees, and streamlines the approval, registration, and payment administration workflows for employers. It also provides managed services; customer enablement and support services; learning and creative services; and strategic planning and services like data consultants, change management experts, and learning strategists to identify and build a plan to achieve learning goals. The company was founded in 1999 and is headquartered in Kitchener, Canada.
Melrose Industries stock logo

#24 - Melrose Industries

OTCMKTS:MLSPF
Stock Price: $6.50 (-$0.31)
PE Ratio: 12.31
Average Trading Volume: 12,322 shares
P/E Ratio: 12.3
Dividend Yield: 3.37%
Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $545.00 (8,284.6% Upside)
Melrose Industries PLC, together with its subsidiaries, engages in the aerospace, automotive, powder metallurgy, and other industrial businesses in the United Kingdom, rest of Europe, North America, and internationally. Its Aerospace segment provides airframe and engine structures, and electrical interconnection systems for the aerospace industry in civil airframe and defense platforms. The company's Automotive segment designs, develops, manufactures, and integrates driveline technologies, including electric vehicle components. Its Powder Metallurgy segment offers precision powder metal parts for the automotive and industrial sectors; and metal powder for powder metallurgy, as well as commercializes additive manufacturing. The company's Other Industrial segment designs, manufactures, and distributes ergonomic products for use in a various working, learning, and healthcare environments; and offers metal hydride hydrogen storage solutions for use in a range of industrial and commercial applications. The company was formerly known as New Melrose Industries PLC and changed its name to Melrose Industries PLC in November 2015. Melrose Industries PLC was founded in 2003 and is headquartered in London, the United Kingdom.
X4 Pharmaceuticals stock logo

#25 - X4 Pharmaceuticals

NASDAQ:XFOR
Stock Price: $1.64 (-$0.05)
PE Ratio: -1.25
Market Cap: $200.42 million
Average Trading Volume: 2.34 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.50 (113.4% Upside)
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Ideas from MarketBeat

My Account -